6. GRANTS	12 Months Ended
Dec. 31, 2019
Research and Development [Abstract]
GRANTS	6. GRANTS In June 2016, the German State of Schleswig-Holstein granted PBAG approximately 874,000 Euros (approximately $1,047,000) for further research and development of the Company's pharmaceutical product Elafin (the “Grant”). The Grant, as amended, covers 50% of eligible research and development costs incurred from December 1, 2015 through October 31, 2020. Research and development expenses for the years ended December 31, 2019 and 2018, were reduced by Grant funds of approximately $128,000 and $306,000, respectively. Grant funds to reimburse approximately $34,000 and $38,000 of such eligible expenses, which were not reimbursed at December 31, 2019 and 2018, respectively, are included in the accompanying consolidated balance sheets as grant funds receivable. During the year ended December 31, 2018, the company received approval from the government to submit certain expenses totaling $177,000 for reimbursement that had been previously expensed under GAAP. This additional Grant reimbursement resulted in grant revenue exceeding research and development expenses for the period. This has resulted in the presentation of net Grant revenue for the year ended December 31, 2018, totaling $107,000.

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 730
-URI http://asc.fasb.org/subtopic&trid=2197926

Name:	us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration